Targeted Oncology· @TargetedOnc · X·· 1 天前评分70
正文 · 原文
#ESMO26 | SAFFRON
After osimertinib progression, can targeting MET help?
Osimertinib + savolitinib improved PFS (7.6 vs 5.4 mo; HR 0.55) and OS (17.8 vs 12.9 mo; HR 0.68) vs chemotherapy in MET-driven EGFR-mutant NSCLC.
— @AmandaSunMD | #ESMO26 Takeover, Oct 25
52 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Targeted Oncology · x.com